Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of ...
BioNTech SE (BNTX) has released an update. BioNTech SE reported a strong third quarter in 2024, with revenues reaching €1.2 ...
Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2 ...
In a report released today, Cory Kasimov from Evercore ISI maintained a Hold rating on BioNTech SE (BNTX – Research Report), with a price target of $110.00. The company’s shares closed yesterday ...
Shares of BioNTech SE (NASDAQ:BNTX – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the fourteen analysts that are presently covering the stock, Marketbeat ...
Driven by the early approval of its updated COVID-19 vaccine, BioNTech far exceeded analysts’ expectations in the third ...
The BioNTech SE ADR BNTX sank 0.63% to $110.88 Tuesday, on what proved to be an all-around rough trading session for the ...
FDA Presses Clinical Hold Button For BioNTech's Partner Late-Stage Trial Of Investigational Lung Cancer Treatment BioNTech's Phase 3 NSCLC trial is paused after varying outcomes. Current ...
BioNTech SE (BNTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yaron Werber ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback